- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510726
Quantitative Evaluation of Muscle Stiffness in Neurological Patients With Muscle Overactivity
Reliability, Validity, and Responsiveness of Shearwave Elastography to Assess Muscle Stiffness in Neurological Population With Muscle Overacivity
Objective:
- to investigate reliability, validity and responsiveness of shearwave elastography (SWE) to assess muscle stiffness of overactive upper or lower limb muscles in different angle joint positions in patients with neurological condition
- to investigate the relationship between muscle stiffness measured by SWE and by MyotonPro
- to investigate the correlation between muscle stiffness measured by SWE and clinical outcomes
Methods: each patient will be assessed three times: two times at an interval of 15 minutes on the same day and one time at an interval of one week at the same time of the day. The following measurements will be made at each evaluation: SWE, MyotonPro, clinical evaluation. SWE and MytotonPro will be taken at different angle joint position.
Outcomes: muscle stiffness measured by SWE and MyotonPro at different angle joint positions, and clinical evaluation (passive range of motion, modified ashworth scale, tardieu scale, fuglmeyer) Hypothesis: SWE is a valid, reliable, and resposive method to assess muscle stiffness in neurological population with muscle overactivity. The results of SWE will be correlated with the results of MyotonPro and with clinical outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1200
- Cliniques universitaires Saint-Luc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- age > 18 years
- hemiparesia/-plegia following neurological condition (TBI, stroke,...)
- > 3 months after injury
- muscle overactivity in lower limb
Exclusion Criteria:
- other neurological or orthopaedic conditions involving the affected limb
- aphasia or major cognitive impairment limiting functional assessment
- botulinum toxin injection in the last 3 months
- previous treatment of muscle overactivity with surgical procedures.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
reliability, validity and responsiveness shearwave elastography (SWE) to assess muscle elasticity
Time Frame: Day 1
|
expressed in m/s.
A smaller shearwave velocity indicates a better outcome.
|
Day 1
|
|
reliability, validity and responsiveness shearwave elastography (SWE) to assess muscle elasticity
Time Frame: Day 1 + 15 minutes
|
expressed in m/s.
A smaller shearwave velocity indicates a better outcome
|
Day 1 + 15 minutes
|
|
reliability, validity and responsiveness shearwave elastography (SWE) to assess muscle elasticity
Time Frame: Day 1 + 7-14 days
|
expressed in m/s.
A smaller shearwave velocity indicates a better outcome
|
Day 1 + 7-14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
muscle stiffness assessment with MyotonPro
Time Frame: two times day 1 at 15minutes interval + 7-14 days later at same time of the day
|
a smaller muscle stiffness indicates a better outcome
|
two times day 1 at 15minutes interval + 7-14 days later at same time of the day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
passive range of motion
Time Frame: day 1 + 7-14 days later at same time of the day
|
expressed in angles °.
The greater the angle, the better the outcome
|
day 1 + 7-14 days later at same time of the day
|
|
modified ashworth scale
Time Frame: day 1 + 7-14 days later at same time of the day
|
minimum score:0; maximum score: 4. A higher score indicates a greater spasticity thus a worse outcome
|
day 1 + 7-14 days later at same time of the day
|
|
Tardieu scale
Time Frame: day 1 + 7-14 days later at same time of the day
|
minimum score:0; maximum score: 4. A higher score indicates a greater spasticity thus a wourse outcome
|
day 1 + 7-14 days later at same time of the day
|
|
Fugl-meyer score (Lower extremity; motor function)
Time Frame: day 1 + 7-14 days later at same time of the day
|
maximum score of 34.
The highest the score, the better the motor function
|
day 1 + 7-14 days later at same time of the day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gaetan Stoquart, MD, PhD, Cliniques universitaires Saint-Luc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/18MAI/217
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.